MSOS ETF Could See Upside From 280E Relief, Analyst Says Hold

280E Relief Seen as Meaningful Catalyst

The analyst flagged broader 280E relief as a significant value driver for the MSOS portfolio, which holds equity stakes in vertically integrated U.S. cannabis operators. Section 280E of the Internal Revenue Code currently bars cannabis businesses from deducting ordinary business expenses. That forces MSOs to pay effective tax rates above 70% in some cases. Legislative or administrative relief would free up cash flow across the sector.

MSOS tracks a basket of MSOs including Curaleaf, Trulieve, Green Thumb Industries, and Verano. These operators have lobbied aggressively for 280E reform, arguing the tax treatment creates competitive disadvantages against illicit markets and limits reinvestment in compliance and product quality.

For full background on this issue, see the CannIntel topic hub on 280E tax relief.

Risk-Reward Calculus Favors Wait-and-See

Despite the tax-reform upside scenario, the Seeking Alpha report recommended a hold rating based on current valuation and policy uncertainty. The analysis didn't disclose specific price targets or risk metrics. But the hold stance reflects broader caution in cannabis equity markets following two years of compressed multiples and limited federal movement on rescheduling or banking reform.

MSOS has underperformed the S&P 500 by over 40 percentage points since its 2020 launch, weighed down by state-level oversupply, pricing compression in mature markets like California and Colorado, and persistent federal prohibition. Net asset value? It sits roughly 60% below the ETF's 2021 peak.

MSO Sector Faces Margin Pressure Absent Reform

Without 280E relief, MSOs continue to face structural margin headwinds that limit their ability to compete on price or invest in technology infrastructure. Operators in states like Michigan and Illinois have reported gross margins below 40% in recent quarters—down from 50%-plus levels in 2021-2022. The tax burden compounds pricing pressure from new license issuance and wholesale flower deflation.

Seed-to-sale tracking costs, compliance labor, and payment-processing fees add another layer of expense that non-cannabis retailers don't face. MSOs have increasingly turned to vertical integration and private-label SKUs to defend margins, but those strategies require capital that 280E makes harder to generate organically. Cash flow remains constrained.

What Investors Are Watching Next

The key variable for MSOS upside is whether Congress or the DEA acts on 280E before the 2027 budget cycle. The DEA's pending rescheduling decision could move cannabis from Schedule I to Schedule III. That would automatically eliminate 280E restrictions. The process has stalled in administrative review since late 2024.

Legislative relief remains possible through the SAFE Banking Act or standalone tax bills, but neither has advanced past committee in the current session. Analysts will also watch Q3 MSO earnings in August for signs that same-store sales are stabilizing in key markets like Florida, Pennsylvania, and New York. Stabilization would be welcome news.